調査レポートカテゴリー： visiongain, 世界, 医療/バイオ

Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) 2016-2026

医薬品リーダーシリーズ：医薬品製造受託機関（CMO）上位30社2016-2026

◆タイトル：Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) 2016-2026
◆商品コード：VGAIN61121
◆調査・発行会社：visiongain
◆発行日：2016年9月
◆ページ数：317
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：製薬
◆販売価格オプション（消費税別）

Sigle User（1名利用）	GBP1,999 ⇒換算￥289,855	見積依頼/購入/質問フォーム
Five User	GBP2,999 ⇒換算￥434,855	見積依頼/購入/質問フォーム
Site License（全社内共有可）	GBP4,999 ⇒換算￥724,855	見積依頼/購入/質問フォーム

※Single UserとDept Licence(Five User)の場合、DRM（デジタル著作権管理）付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、医薬品製造受託機関（CMO）上位30社について調査・分析し、以下の構成でお届けいたします。
1. レポート概要

2. 医薬品受託製造の概要2016

3. 北米の主要CMO（製造受託機関）

4. 欧州の主要製造受託機関

5. 日本の主要医薬品製造受託機関

6. 先進国市場の主要APIスペシャリスト

7. 中国の主要医薬品製造受託企業

8. インドの主要医薬品製造受託企業

9. 結論

In its updated report, visiongain provides revenues to 2026 for the world pharmaceutical contract manufacturing organisations (CMO) market.

This report also analyses leading companies in pharmaceutical contract manufacturing. The demand for outsourced drug production has grown rapidly in the past 10 years. The world market for pharma contract manufacturing was worth $61.6bn in 2015, having grown by more than 6% from 2014.

The new study predicts strong growth in that industry’s revenue, reaching $84.0bn worldwide in 2020, with further expansion expected.

Our 317-page report provides 185 tables, 110 figures and analysis of 30 leading companies.

The content of each profile differs, depending on the organisation. In general, though, a profile gives you the following information:
• Overview of the company’s contract manufacturing services and operations
• Analysis of recent financial performance – annual revenue for CMO services, including some data on operating profit and margins
• Assessment of developments – activities, acquisitions, production capacity, deals, new service offerings and collaborations
• SWOT analysis – a firm’s strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2015 onwards
• Forecasting of pharmaceutical manufacturing revenue to 2026, as well as projected operating profit and margin for some companies.

Leading Pharmaceutical Contract Manufacturing Organisations profiled in this report:
• Catalent
• Patheon
• Baxter
• AbbVie
• Pfizer
• Lonza
• Evonik Degussa
• Royal DSM
• Boehringer Ingelheim
• Fareva
• Aenova
• Famar
• Vetter
• Almac
• Delpharm
• Siegfried
• Corden
• Recipharm
• Aesica
• Nipro
• Daito
• Teva API
• Esteve Quimica
• Euticals
• Zhejiang Hisun Pharmaceuticals
• Zhejiang Huahai Pharmaceuticals
• Shandong Xinhua Pharmaceuticals
• Aurobindo Pharma
• Divis Laboratories
• Dr. Reddy’s Laboratories

【レポートの目次】

1. Report Overview
1.1 Leading Contract Manufacturing Organisations (CMOs) Overview
1.2 Benefits of This Report
1.3 How This Report Delivers Information
1.4 Main Questions This Report Answers
1.5 Who is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Related Reports
1.9 About Visiongain

2. Introduction to Pharmaceutical Contract Manufacturing, 2016
2.1 What Services Do Contract Manufacturers Offer?
2.1.1 Why Do Firms Outsource Manufacturing?
2.1.2 What Is Driving Demand for Contract Manufacturing Services?
2.2 The Pharmaceutical Contract Manufacturing Market, 2015
2.2.1 Where is Supply and Demand Highest for Contract Manufacturing Services?
2.3 Outlook for the Pharmaceutical Contract Manufacturing Market 2016-2026
2.4 Driving and Restrictive Forces for Pharmaceutical Contract Manufacturing, 2016-2026
2.4.1 Pharmaceutical Contract Manufacturing: Market Drivers 2016-2026
2.4.2 Pharmaceutical Contract Manufacturing: Market Restraints 2016-2026
2.5 Who Are the Leading Pharmaceutical Contract Manufacturers in 2015?

3. Leading CMOs in North America
3.1 Catalent Pharma Solutions- the World’s Leading CMO
3.1.1 Catalent: Manufacturing Services and Capabilities
3.1.2 Divisional Segmentation – Breaking Down Catalent’s Service
3.1.3 Catalent Pharma’s Revenue Growth, 2010-2014
3.1.4 Sustained Growth in Oral Products: Catalent Pharma’s Divisional Performance, 2010-2014
3.1.5 Catalent Is Expanding its Oral Technologies Division
3.1.6 Quadrupling Biopharmaceutical Manufacturing Capacity
3.1.7 Expansion of Packaging Services in Asia-Pacific and Europe: 2015
3.1.8 Adding New Early-Stage Development Services
3.1.9 Expansion in Japan – Growth Prospects for Catalent
3.1.10 New Business Contracts 2014-2015
3.1.11 Catalent New Products Launch
3.1.12 Catalent: Opportunities for Growth 2016-2026
3.1.13 Catalent: Mild Growth in Revenue, 2016-2026
3.2 Patheon – One of the Top 3 CMOs
3.2.1 Patheon – Global leader in Pharmaceutical Development Services
3.2.2 Contract Manufacturing Services at Patheon
3.2.3 Steady Revenue Growth 2010-2015
3.2.4 DPx Holdings: Developments
3.2.5 Adding New Formulations and Formulation Development Services
3.2.6 Reassessing Manufacturing Capacity
3.2.7 Expanding Services Through Acquisition, 2015
3.2.8 Patheon: SWOT Analysis 2016-2026
3.2.9 Patheon: Contract Manufacturing Revenue Forecast 2016-2026
3.3 Baxter BioPharma Solutions
3.3.1 Baxter BioPharma is the Global Leader in Sterile Fill and Finish
3.3.2 Historic Revenue Performance 2010-2015
3.3.3 Baxter BioPharma SWOT Analysis 2016-2026
3.3.4 Baxter BioPharma Revenue Forecast 2016-2026
3.4 AbbVie Contract Manufacturing
3.4.1 AbbVie Offers Full-Service Contract Manufacturing
3.4.2 Expanding and Adding New Services: 2013-2014
3.4.3 AbbVie Contract Manufacturing: Revenue 2011-2015
3.4.4 Biologics and HPAPIs Are an Opportunity for Growth 2016-2026
3.4.5 AbbVie Contract Manufacturing Revenue Forecast 2016-2026
3.5 Pfizer CentreOne
3.5.1 Pfizer CentreSource: Historic Revenue Performance, 2010-2015
3.5.2 Will Hospira Acquisition Lead to Revenue Growth in Future?
3.5.3 Outlook for CentreOne: Revenue Forecast 2016-2026

4. Leading European Contract Manufacturing Organisations
4.1 Lonza
4.1.1 Lonza Is a Leader in Biologics Manufacturing
4.1.2 Lonza Contract Manufacturing and Development: 2010-2015
4.1.3 Investing in Advanced Biological Drug Sectors
4.1.4 The Promise of Antibody-Drug Conjugates (ADCs)
4.1.5 The Regenerative Medicine Future in Japan
4.1.6 Lonza: SWOT Analysis 2016-2026
4.1.7 Biologics and Efficiency Savings Will Drive Growth in Revenue and Operating Profit for Lonza 2016-2026
4.2 Evonik Degussa
4.2.1 Investing in API and Drug Delivery Services
4.2.2 Moderate Growth in Pharmaceutical Manufacturing Services, 2010-2015
4.2.3 Evonik Is a HPAPI Specialist
4.2.4 Evonik Continues to Grow Across All Segments
4.2.5 How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market?
4.2.6 Evonik Degussa: Revenue Forecast 2016-2026
4.3 Royal DSM
4.3.1 Amplified Revenue Growth in Pharma Manufacturing 2010-2014
4.3.2 DSM Pharmaceuticals Products/DPx Holdings: Manufacturing Services 2010-2015
4.3.3 DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing
4.3.4 DPx Holdings: A New Pharma Leader
4.3.5 Investing in Biopharma Manufacturing
4.3.6 Expanding API Manufacturing
4.3.7 Generics and Biologics Are an Opportunity for Growth, 2015-2026
4.3.8 DSM Pharmaceuticals Products: Revenue Forecast 2016-2026
4.4 Boehringer Ingelheim Contract Manufacturing
4.4.1 Expanding Biopharmaceuticals Manufacturing Services in China
4.4.2 Production Through to Fill and Finished Biopharmaceuticals
4.4.3 A Track Record of Production for 29 Biopharma Products
4.4.4 Increasing Revenue from Contract Manufacturing, 2010-2014
4.4.5 Pulling Out of Small Molecule API Manufacturing
4.4.6 Expanding through New Services
4.4.7 Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth 2016-2026
4.4.8 Boehringer Ingelheim: Revenue Forecast 2016-2026
4.5 Fareva
4.5.1 Fareva Has 35 Years’ Manufacturing Experience
4.5.2 Revenue Growth through Acquisitions: 2010-2015
4.5.3 Fareva SWOT Analysis: 2016-2026
4.5.4 Fareva Revenue Forecast: 2016-2026
4.6 Aenova Group
4.6.1 Acquisition of Haupt Creates European CMO Giant
4.6.2 Aenova’s Ever Expanding Manufacturing Capacity
4.6.3 Aenova’s Revenue 2010-2015: Organic Growth and Acquisitions
4.6.4 Aenova’s Competitive Position in the Contract Manufacturing Market: SWOT Analysis 2016
4.6.5 Becoming a Leading Contract Manufacturer: Aenova Revenue Forecast 2016-2026
4.7 Famar
4.7.1 Famar Is an Expert in Lyophilisation
4.7.2 Sustained Growth in Famar’s Revenue: 2010-2015
4.7.3 Expanding Outside Europe
4.7.4 Further Site Acquisitions Are an Opportunity for Growth 2016-2026
4.7.5 How Will Famar Perform 2016-2026?
4.8 Vetter Pharmaceutical
4.8.1 Vetter is an Injectable Manufacturing Specialist
4.8.2 Rapidly Growing Revenue in the US and Germany: 2010-2015
4.8.3 Services, Collaborations and Differentiating Factors
4.8.4 Expanding Services in US and Asia
4.8.5 Biologics Are an Opportunity for Growth for Vetter 2016-2026
4.8.6 Vetter Outlook: Revenue Forecast 2016-2026
4.9 Almac Group
4.9.1 Almac’s Manufacturing Services
4.9.2 Almac Outpaces the Market: 2011-2015
4.9.3 Almac Adding Capacity Globally
4.9.4 New Services Added 2012-2015
4.9.5 Almac Group: Contract Manufacturing Market Outlook 2016-2026
4.9.6 How Will Almac Group Perform 2016-2026?
4.10 Delpharm
4.10.1 Finished Dosage Form Manufacturing for Developed Markets
4.10.2 Delpharm: Rapid Revenue Growth Via Acquisitions, 2010-2015
4.10.3 Delpharm: Outlook and Prospects for Growth 2016-2026
4.10.4 Generics Will Drive Revenue Growth for Delpharm 2016-2026
4.11 Siegfried
4.11.1 Siegfried’s Acquisitions, 2010-2015
4.11.2 Expanding Siegfried’s Manufacturing Footprint Globally
4.11.3 Expanding High Potency API Capabilities
4.11.4 Siegfried: Financial Performance 2010-2015
4.11.5 Siegfried’s Characteristics within the Contract Manufacturing Market: SWOT Analysis 2016
4.11.6 Continued Revenue Growth for Siegfried 2016-2026
4.12 Corden Pharmaceutical
4.12.1 CordenPharma Service Division
4.12.2 CordenPharma Emerging in the API Market
4.12.3 Investments in Highly Potent Capabilities
4.12.4 CordenPharma: SWOT Analysis 2016-2026
4.13 Recipharm
4.13.1 Contract Development and Manufacturing Services
4.13.2 Recipharm: Financial Performance 2010-2015
4.13.3 Recipharm Invests in Facility Expansion
4.13.4 Recipharm Growing in the Development and Technology Market Through Acquisitions
4.13.5 Recipharm: Opportunities for Growth 2016-2026
4.13.6 Outlook for Recipharm: Revenue Forecast 2016-2026
4.14 Aesica Pharmaceuticals
4.14.1 Aesica Manufactures APIs and Finished Dosage Forms
4.14.2 Acquisitions Drive Revenue Growth but Operational Margins Have Declined, 2010-2015
4.14.3 Partnering with Academia for Innovative Solutions
4.14.4 Growth through Acquisitions and Internal Expansion
4.14.5 Aesica: Opportunities for Expansion 2016-2026
4.14.6 Forecast Aesica Financial Performance, 2016-2026

5. Leading Japanese Pharma Contract Manufacturing Organisations
5.1 Nipro Corporation: Japan’s Leading CMO
5.1.1 Nipro Pharmaceutical Contract Manufacturing Capabilities
5.1.2 Nipro: Decline in Revenue But increasing Operating Profits 2010-2015
5.1.3 Biosimilars and Anti-Cancer Drugs Are Opportunities for Future Growth: SWOT Analysis 2016-2026
5.1.4 Nipro Revenue and Profitability Forecast 2016-2026
5.2 Daito Pharmaceutical
5.2.1 Daito Has a Portfolio of More than 30 APIs
5.2.2 Rapid Growth in Revenue and Operational Profit: Daito Financial Performance 2010-2015
5.2.3 Daito Is Well-Placed for Asian Market Growth – SWOT Analysis 2016-2026
5.2.4 Sustained Growth in Revenue and Operating Profit for Daito, 2016-2026

6. Leading Developed-Market API Specialists
6.1 Teva API
6.1.1 API Manufacturing Services
6.1.2 Teva API: Financial Performance 2010-2015
6.1.3 Building a Footprint in Mexico, India and China
6.1.4 Teva API: SWOT Analysis 2016-2026
6.1.5 Outlook for Teva API: Revenue Forecast 2015-2025
6.2 Esteve Química
6.2.1 Esteve Química Manufactures APIs for Developed and Emerging Markets
6.2.2 Expanding in The US, 2015
6.2.3 Esteve Química: SWOT Analysis 2016-2026
6.3 Euticals
6.3.1 Euticals Manufactures More than 200 APIs
6.3.2 Acquisitions Drive Growth 2010-2015
6.3.3 Adding Capacity for Finished Dosage Forms
6.3.4 Asian Expansion Is an Opportunity for Growth 2016-2026
6.3.5 Euticals: Revenue Forecast 2016-2026

7. Leading Chinese Pharmaceutical Conctract Manufacturers
7.1 Zhejiang Hisun Pharmaceutical
7.1.1 API Manufacturing for Markets Worldwide
7.1.2 Zhejiang Hisun’s Rapid Growth in API Revenue Grows, 2010-2015
7.1.3 Moving Into International Drug Marketing
7.1.4 Zhejiang Hisun: Opportunities for Growth 2016-2026
7.1.5 Zhejiang Hisun: Strong API Revenue Growth 2016-2026
7.2 Zhejiang Huahai Pharmaceuticals
7.2.1 Zhejiang Huahai Is a Market Leader Within The Antihypertensive API Market
7.2.2 Zhejiang Huahai: Contract Manufacturing Performance 2010-2015
7.2.3 Expanding in the US Generic Drugs Market
7.2.4 Zhejiang Huahai: SWOT Analysis, 2016-2026
7.2.5 Zhejiang Huahai: Revenue Forecast, 2016-2026
7.3 Shandong Xinhua Pharmaceutical
7.3.1 Experience in APIs and Finished Dosage Forms
7.3.2 Shandong Xinhua: Strong Revenue Growth 2010-2015
7.3.3 Growing through Joint Ventures
7.3.4 Looking to Expand in the US and EU 2016-2026
7.3.5 Shandong Xinhua Pharmaceutical: Revenue Forecast 2016-2026

8. Leading Indian Pharmaceutical Contract Manufacturers
8.1 Aurobindo Pharma
8.1.1 API Manufacturing Services
8.1.2 Aurobindo Pharma: Steady Revenue Growth 2010-2015
8.1.3 Aurobindo Expanding Outside of Antibacterials
8.1.4 Aurobindo: Opportunities for Expansion 2016-2026
8.1.5 How Will Aurobindo’s Contract Manufacturing Division Perform 2016-2026?
8.2 Divis Laboratories
8.2.1 Divis Laboratories and the Contract Manufacturing Industry
8.2.2 Divis Laboratories: A Rapidly Growing CMO, 2010-2014
8.2.3 Divis Laboratories: API Manufacturing Outlook 2016-2026
8.2.4 Divis Laboratories: API Manufacturing Revenue Forecast, 2016-2026
8.3 Dr. Reddy’s Laboratories
8.3.1 API and FDF Manufacturing Services
8.3.2 Dr. Reddy’s PSAI: Strong Revenue Growth 2011-2015
8.3.3 Advancing in Complex Drug Manufacturing
8.3.4 Expanding in the European Manufacturing Market
8.3.5 Dr. Reddy’s PSAI Division: Revenue Forecast 2016-2026

9. Conclusions of the Study
9.1 What Has Driven Growth for CMO Market Leaders in Recent Years?
9.2 Strategies for Growth: Prospects For Leading CMOs, 2016-2026
9.3 High Demand for Biopharmaceutical Manufacturing Services
9.4 Investing in Novel Technologies
9.5 Outlook for API Manufacturers

List of Tables
Table 1.1 Leading Pharmaceutical Contract Manufacturing Organisations: Rank, Revenue ($m), Market Share (%), 2015
Table 1.2 Foreign Currency Exchange Rates Used: 2015 Average Exchange Rate to $US
Table 2.1 Benefits and Drawbacks to Outsourcing Pharmaceutical Manufacturing, 2016
Table 2.2 Contract Manufacturing Market Total Revenue: Total Revenue ($bn), Annual Growth (%), 2012-2014
Table 2.3 Contract Manufacturing Market by Service: Market Size ($bn), Market Share (%), 2014
Table 2.4 Contract Manufacturing Market by Leading Country: Market Size ($bn), Market Share (%), 2014
Table 2.5 Contract Manufacturing Market Forecast by Service: Market Size ($bn), Market Share (%), CAGR (%), 2015, 2020 and 2026
Table 2.6 Leading Pharmaceutical Contract Manufacturing Organisations: Rank, Revenue ($m), Market Share (%), 2015
Table 3.1 Catalent Details, 2016
Table 3.2 Catalent Facility Details, 2016
Table 3.3 Catalent Financial Performance: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2010-2015
Table 3.4 Catalent Financial Performance by Product Type: Revenue ($m), Revenue Share (%), 2015
Table 3.5 Catalent Financial Performance by Division: Revenue ($m), Annual Growth Rate (%), Revenue Share (%), CAGR (%), 2010-2015
Table 3.6 Catalent New Products Launch: New Products, Annual growth (%), CAGR (%), 2012-2015
Table 3.7 Catalent Pharma SWOT Analysis, 2016
Table 3.8 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2014-2019
Table 3.9 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2020-2026
Table 3.10 Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2015-2020
Table 3.11 Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2019-2025
Table 3.12 Patheon Details, 2016
Table 3.13 Patheon Manufacturing Facilities, 2014
Table 3.14 Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2010-2015
Table 3.15 Patheon: SWOT Analysis, 2016
Table 3.16 Forecast Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2015-2026
Table 3.17 Baxter BioPharma Solutions Details, 2016
Table 3.18 Baxter BioPharma Solutions: Facilities and Services Offered, 2015
Table 3.19 Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2015
Table 3.20 Baxter BioPharma Solutions SWOT Analysis, 2016
Table 3.21 Forecast Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2015-2026
Table 3.22 AbbVie Contract Manufacturing: Details, 2016
Table 3.23 AbbVie Contract Manufacturing Facility Capabilities, 2015
Table 3.24 AbbVie Pharmaceutical Manufacturing: Revenue ($m) Annual Growth Rate (%), 2011-2015
Table 3.25 AbbVie Contract Manufacturing SWOT Analysis, 2016
Table 3.26 Forecast AbbVie Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2015-2026
Table 3.27 Pfizer CentreOne Details, 2016
Table 3.28 Pfizer CentreSource: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2015
Table 3.29 Pfizer CentreOne SWOT Analysis, 2016
Table 3.30 Forecast Pfizer CentreOne Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2015-2026
Table 4.1 Lonza Details, 2016
Table 4.2 Selected Lonza Pharmaceutical and Biotech Manufacturing and Development Agreements, 2010-2015
Table 4.3 Lonza Pharma & Biotech Department: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2010-2015
Table 4.4 ADCs Approved and in Late Stage Clinical Development, 2014
Table 4.5 Lonza SWOT Analysis, 2016
Table 4.6 Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2015-2020
Table 4.7 Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2020-2026
Table 4.8 Evonik Degussa Details, 2016
Table 4.9 Evonik Health and Nutrition: R&D and Production Sites by Region, 2015
Table 4.10 Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2015
Table 4.11 Evonik Pharmaceutical Manufacturing: SWOT Analysis, 2016
Table 4.12 Forecast Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2015-2026
Table 4.13 Royal DSM Details, 2016
Table 4.14 Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%) 2010-2015
Table 4.15 DSM Pharmaceutical Products (DPP)/DPx Holdings Division: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2015
Table 4.16 DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), Annual Growth (%), CAGR (%), 2010-2015
Table 4.17 DSM Pharmaceutical Manufacturing: SWOT Analysis, 2016
Table 4.18 Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2015-2020
Table 4.19 Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2020-2026
Table 4.20 Boehringer Ingelheim Biopharmaceuticals Details, 2016
Table 4.21 Boehringer Ingelheim Total Pharmaceutical Manufacturing Capacity: Reactor Size and Number of Units by CMO Service, 2014
Table 4.22 Products Developed by Boehringer Ingelheim Biopharmaceuticals, 1983-2014
Table 4.23 Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2010-2015
Table 4.24 Boehringer Ingelheim: SWOT Analysis, 2016
Table 4.25 Forecast Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2015-2026
Table 4.26 Fareva Details, 2016
Table 4.27 Fareva Manufacturing Facilities, 2015
Table 4.28 Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2015
Table 4.29 Fareva: SWOT Analysis, 2016
Table 4.30 Forecast Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2015-2026
Table 4.31 Aenova Group Details, 2016
Table 4.32 Aenova Group Manufacturing Capacity by Dosage Form, 2015
Table 4.33 Aenova Group Manufacturing Facility Details, 2016
Table 4.34 Aenova Group Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2011-2015
Table 4.35 Aenova Group SWOT Analysis, 2016
Table 4.36 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2015-2020
Table 4.37 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2020-2026
Table 4.38 Famar Details, 2016
Table 4.39 Famar Pharmaceutical Manufacturing Facilities, 2014
Table 4.40 Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2015
Table 4.41 Famar: SWOT Analysis, 2016
Table 4.42 Forecast Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2015-2026
Table 4.43 Vetter Details, 2016
Table 4.44 Vetter Pharmaceutical Facilities, 2016
Table 4.45 Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2015
Table 4.46 Vetter: SWOT Analysis, 2016
Table 4.47 Forecast Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2015-2026
Table 4.48 Almac Details, 2016
Table 4.49 Almac Pharmaceutical Manufacturing Facilities Details , 2014
Table 4.50 Almac Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2011-2015
Table 4.51 Almac: SWOT Analysis, 2016
Table 4.52 Forecast Almac Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2015-2020
Table 4.53 Forecast Almac Pharmaceuticals: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), 2020-2026
Table 4.54 Delpharm Details, 2016
Table 4.55 Delpharm: Facilities and Services, 2015
Table 4.56 Delpharm: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2015
Table 4.57 Delpharm: SWOT Analysis, 2016
Table 4.58 Forecast Delpharm Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2015-2026
Table 4.59 Siegfried Details, 2016
Table 4.60 Siegfried Pharmaceutical Manufacturing Facilities Details, 2016
Table 4.61 Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2010-2015
Table 4.62 Siegfried Pharmaceutical Manufacturing Revenue by Service: API Revenue ($m), Drug Product Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2010-2015
Table 4.63 Siegfried: SWOT Analysis, 2016
Table 4.64 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2015-2020
Table 4.65 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2020-2026
Table 4.66 CordenPharma Details, 2016
Table 4.67 CordenPharma Facilities and Service Details, 2015
Table 4.68 Corden Pharmaceuticals: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2015
Table 4.69 Corden Pharmaceuticals SWOT Analysis, 2016
Table 4.70 Recipharm Details, 2016
Table 4.71 Recipharm: Facility Details and Services, 2014
Table 4.72 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2010-2015
Table 4.73 Recipharm Manufacturing Revenue by Client Size: Revenue ($m), Share of Total Revenues (%), 2015
Table 4.74 Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), Share of Total Revenues (%), 2014
Table 4.75 Recipharm: SWOT Analysis, 2016
Table 4.76 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2015-2020
Table 4.77 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2020-2026
Table 4.78 Aesica Details, 2016
Table 4.79 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2010-2015
Table 4.80 Aesica SWOT Analysis, 2016
Table 4.81 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2015-2020
Table 4.82 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2020-2026
Table 5.1 Nipro Pharma Details, 2016
Table 5.2 Nipro Pharmaceutical Contract Manufacturing Capabilities: 2010-2015
Table 5.3 Nipro Pharmaceutical Contract Manufacturing: Annual Production Capacity, 2014
Table 5.4 Nipro Pharmaceutical Contract Manufacturing Financial Performance: Revenue ($m), Revenue (¥m), Operating Profit ($m), Operating Profit (¥m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2010-2015
Table 5.5 Nipro Pharmaceutical Contract Manufacturing SWOT Analysis, 2016
Table 5.6 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2015-2020
Table 5.7 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2020-2026
Table 5.8 Daito Pharmaceuticals: Details, 2016
Table 5.9 Daito Pharmaceuticals Financial Performance: Revenue ($m), Revenue (¥m), Operating Profit ($m), Operating Profit (¥m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2010-2015
Table 5.10 Daito Pharmaceuticals SWOT Analysis, 2016
Table 5.11 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2015-2020
Table 5.12 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2020-2026
Table 6.1 Teva API Details, 2016
Table 6.2 Teva API: Site Acquisitions, 1980- 2011
Table 6.3 Teva API: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2015
Table 6.4 Teva API SWOT Analysis, 2016
Table 6.5 Forecast Teva API Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2015-2026
Table 6.6 Esteve Química Details, 2016
Table 6.7 Esteve Química SWOT Analysis, 2016
Table 6.8 Euticals Details, 2016
Table 6.9 Euticals Facility Details: Production Capacity (m3) and Key Products, 2015
Table 6.10 Euticals Cumulative Regulatory Filings by Region/Country: Filings, Share of Total (%), 2014
Table 6.11 Euticals: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2015
Table 6.12 Euticals Revenue by Product Class: Revenue ($m), Share of Total (%), 2015
Table 6.13 Euticals Revenue by Region: Revenue ($m), Share of Total (%), 2015
Table 6.14 Euticals SWOT Analysis, 2016
Table 6.15 Forecast Euticals Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2015-2026
Table 7.1 Zhejiang Hisun Pharmaceuticals Details, 2016
Table 7.2 Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2015
Table 7.3 Zhejiang Hisun Manufacturing: SWOT Analysis, 2016
Table 7.4 Forecast Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2015-2026
Table 7.5 Zhejiang Huahai Pharmaceuticals Details, 2015
Table 7.6 Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2015
Table 7.7 Zhejiang Huahai Contract Manufacturing: SWOT Analysis, 2016
Table 7.8 Forecast Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2015-2026
Table 7.9 Shandong Xinhua Pharmaceuticals Details, 2016
Table 7.10 Shandong Xinhua Pharmaceutical Production Capacity by Dosage Form, 2015
Table 7.11 Shandong Xinhua: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2015
Table 7.12 Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 2014
Table 7.13 Shandong Xinhua Manufacturing: SWOT Analysis, 2016
Table 7.14 Forecast Shandong Xinhua Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2015-2026
Table 8.1 Aurobindo Pharma Details, 2016
Table 8.2 Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2015
Table 8.3 Aurobindo Contract Manufacturing Revenue by API Class: Revenue ($m), Revenue Share (%), 2014
Table 8.4 Aurobindo Contract Manufacturing: SWOT Analysis, 2016
Table 8.5 Forecast Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2015-2026
Table 8.6 Divis Laboratories Details, 2016
Table 8.7 Divis Laboratories: Facility Details, Production Capacity and Services, 2015
Table 8.8 Divis Laboratories: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2010-2015
Table 8.9 Divis Laboratories Revenue Distribution: Revenue ($m), Share of Total (%), 2014
Table 8.10 Divis Laboratories Revenue by Region: Revenue ($m), Share of Total (%), 2014
Table 8.11 Divis Laboratories Contract Manufacturing: SWOT Analysis, 2016
Table 8.12 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m),EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2015-2020
Table 8.13 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2020-2026
Table 8.14 Dr. Reddy’s Laboratories Details, 2016
Table 8.15 Dr. Reddy’s Laboratories Cumulative Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), 1987-2014
Table 8.16 Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2015
Table 8.17 Dr. Reddy’s Laboratories Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), FY 2015
Table 8.18 Dr. Reddy’s Laboratories: Contract Manufacturing Revenue ($m) by Regional Market and Revenue Share (%), FY 2014
Table 8.19 Dr. Reddy’s Laboratories: SWOT Analysis, 2016
Table 8.20 Forecast Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2015-2026
Table 9.1 Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), Annual Growth Rate (%), CAGR (%), 2010-2015
Table 9.2 CMOs by Absolute Change in Revenue ($m): Annual Revenue ($m), Absolute Change in Revenue ($m), 2010-2015
Table 9.3 Leading CMOs: Combined Annual Revenue ($m), Annual Growth (%), Market Share (%), CAGR (%), 2015-2026
Table 9.4 Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), Annual Growth Rate (%), CAGR (%), 2015-2026
Table 9.5 CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2015-2020
Table 9.6 CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2020-2026

List of Figures
Figure 1.1 Segmentation of Contract Manufacturing Organisations, 2016
Figure 2.1 Selected Services Contracted to CMOs by Developmental Stage, 2016
Figure 2.2 Contract Manufacturing Market Total Revenue: Total Revenue ($bn), 2012-2014
Figure 2.3 Contract Manufacturing Market by Service: Market Share (%), 2014
Figure 2.4 Contract Manufacturing Market by Leading Country: Market Share (%), 2014
Figure 2.5 Contract Manufacturing Market Forecast by Service: Market Size ($bn), 2015, 2020 and 2026
Figure 2.6 Pharmaceutical Contract Manufacturing: Drivers and Restraints, 2016-2026
Figure 3.1 Catalent Facilities by Region, 2015
Figure 3.2 Catalent Facilities by Service Offered, 2015
Figure 3.3 Catalent Financial Performance: Revenue ($m), 2010-2015
Figure 3.4 Catalent Financial Performance by Product Type: Revenue Share (%), 2015
Figure 3.5 Catalent Financial Performance by Division: Revenue ($m), 2010-2015
Figure 3.6 Catalent New Products Launch: New products, 2012-2015
Figure 3.7 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), 2015-2020
Figure 3.8 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), 2020-2026
Figure 3.9 Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), 2015-2026
Figure 3.10 Patheon Pharmaceutical Development Projects (%) by Phase, 2014
Figure 3.11 Patheon Pharmaceutical Manufacturing Projects by Client Size: Proportion of Total Revenue (%), 2014
Figure 3.12 Patheon Pharmaceutical Manufacturing: Revenue ($m), 2010-2015
Figure 3.13 Forecast Patheon Pharmaceutical Manufacturing: Revenue ($m), 2015-2026
Figure 3.14 Forecast DPx Holdings Performance by Equity Partner: Revenue ($m), 2015-2026
Figure 3.15 Baxter BioPharma Manufacturing: Revenue ($m), 2010-2015
Figure 3.16 Forecast Baxter BioPharma Manufacturing: Revenue ($m), 2015-2026
Figure 3.17 AbbVie Pharmaceutical Manufacturing: Revenue ($m)*, 2011-2015
Figure 3.18 Forecast AbbVie Pharmaceutical Manufacturing: Revenue ($m), 2015-2026
Figure 3.19 Pfizer CentreOne: Revenue ($m), 2010-2015
Figure 3.20 Forecast Pfizer CentreOne Manufacturing: Revenue ($m), 2015-2026
Figure 4.1 Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2010-2015
Figure 4.2 Lonza Custom Manufacturing by Regional Market: Revenue Share (%), 2015
Figure 4.3 Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2015-2020
Figure 4.4 Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2020-2026
Figure 4.5 Evonik Health and Nutrition: R&D and Production Sites (%) by Region, 2015
Figure 4.6 Evonik Pharmaceutical Manufacturing: Revenue ($m), 2010-2015
Figure 4.7 Forecast Evonik Pharmaceutical Manufacturing: Revenue ($m), 2015-2026
Figure 4.8 Royal DSM Pharmaceutical Manufacturing: Revenue ($m), 2010-2015
Figure 4.9 DSM Pharmaceutical Products (DPP)/ DPx Holdings Division: Revenue ($m), 2010-2015
Figure 4.10 DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), 2010-2015
Figure 4.11 Forecast DPx Holdings Performance by Equity Partner: Revenue ($m), 2015-2026
Figure 4.12 Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), 2015-2026
Figure 4.13 Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2010-2015
Figure 4.14 Forecast Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2015-2026
Figure 4.15 Fareva Pharmaceutical Manufacturing: Revenue ($m), 2010-2015
Figure 4.16 Forecast Fareva Pharmaceutical Manufacturing: Revenue ($m), 2015-2026
Figure 4.17 Aenova Group Pharmaceutical Manufacturing: Revenue ($m), 2011-2015
Figure 4.18 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), 2015-2020
Figure 4.19 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), 2020-2026
Figure 4.20 Famar Pharmaceutical Manufacturing: Revenue ($m), 2010-2015
Figure 4.21 Forecast Famar Pharmaceutical Manufacturing: Revenue ($m), 2015-2026
Figure 4.22 Vetter Pharmaceutical Manufacturing: Revenue ($m), 2010-2015
Figure 4.23 Forecast Vetter Pharmaceutical Manufacturing: Revenue ($m), 2015-2026
Figure 4.24 Almac Pharmaceutical Manufacturing: Revenue ($m), 2011-2015
Figure 4.25 Forecast Almac Pharmaceutical Manufacturing: Revenue ($m), 2015-2020
Figure 4.26 Forecast Almac Pharmaceuticals: Revenue ($m), 2020-2026
Figure 4.27 Delpharm: Revenue ($m), 2010-2015
Figure 4.28 Forecast Delpharm Pharmaceutical Manufacturing: Revenue ($m), 2015-2026
Figure 4.29 Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2010-2015
Figure 4.30 Siegfried Pharmaceutical Manufacturing Revenue by Service: API Revenue ($m), Drug Product Revenue ($m), 2010-2015
Figure 4.31 Siegfried Pharmaceutical Manufacturing Revenue by Customer Location: Revenue Share (%), 2014
Figure 4.32 Siegfried Pharmaceutical Manufacturing Revenue by Customer Location: Revenue Share (%), 2015
Figure 4.33 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2015-2020
Figure 4.34 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2020-2026
Figure 4.35 Corden Pharmaceuticals: Revenue ($m), 2012-2015
Figure 4.36 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2010-2015
Figure 4.37 Recipharm Manufacturing Revenue by Client: Share of Total Revenues (%), 2015
Figure 4.38 Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), 2014
Figure 4.39 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2015-2020
Figure 4.40 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2020-2026
Figure 4.41 Aesica Pharmaceuticals: Revenue ($m)*, Operating Profit ($m)*, Operating Margin (%), 2010-2015
Figure 4.42 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2015-2020
Figure 4.43 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2020-2026
Figure 5.1 Nipro Pharmaceutical Contract Manufacturing Capabilities: Orally Administered Drugs, Injectables, External Preparations, 2010-2015
Figure 5.2 Nipro Pharmaceuticals Financial Performance: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2010-2015
Figure 5.3 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2015-2020
Figure 5.4 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2020-2026
Figure 5.5 Daito Pharmaceuticals Financial Performance: Revenue (¥m), Operating Profit (¥m), Operating Margin (%), 2010-2015
Figure 5.6 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2015-2020
Figure 5.7 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2020-2026
Figure 6.1 Teva API: Revenue ($m), 2010-2015
Figure 6.2 Forecast Teva API Manufacturing: Revenue ($m), 2015-2026
Figure 6.3 Euticals Cumulative Regulatory Filings by Region/Country: Share of Total (%), 2014
Figure 6.4 Euticals: Revenue ($m), 2010-2015
Figure 6.5 Euticals Revenue by Product Class: Share of Total Revenues (%), 2015
Figure 6.6 Euticals Revenue by Region: Share of Total Revenues (%), 2015
Figure 6.7 Forecast Euticals Pharmaceutical Manufacturing: Revenue ($m), 2015-2026
Figure 7.1 Zhejiang Hisun Contract Manufacturing: Revenue ($m), 2010-2015
Figure 7.2 Forecast Zhejiang Hisun Contract Manufacturing: Revenue ($m), 2015-2026
Figure 7.3 Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2010-2015
Figure 7.4 Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2015-2026
Figure 7.5 Shandong Xinhua: Revenue ($m), 2010-2015
Figure 7.6 Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 1H 2014
Figure 7.7 Forecast Shandong Xinhua Manufacturing: Revenue ($m), 2015-2026
Figure 8.1 Aurobindo Contract Manufacturing: Revenue ($m), 2010-2015
Figure 8.2 Aurobindo Contract Manufacturing: Revenue Share (%), 2014
Figure 8.3 Forecast Aurobindo Contract Manufacturing: Revenue ($m), 2015-2026
Figure 8.4 Divis Laboratories Contract Manufacturing: Revenue ($m), EBTDA ($m), EBITDA Margin (%), 2010-2015
Figure 8.5 Divis Laboratories Revenue Distribution: Revenue ($m), 2015
Figure 8.6 Divis Laboratories Revenue by Region: Share of Total (%), 2014
Figure 8.7 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), 2015-2020
Figure 8.8 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), 2020-2026
Figure 8.9 Dr. Reddy’s Laboratories Cumulative Drug Master File (DMF) Applications: Accepted by Region (%), 1987-2014
Figure 8.10 Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), 2010-2015
Figure 8.11 Dr. Reddy’s Laboratories Drug Master File (DMF) Applications: Accepted Applications by Region (%), FY 2015
Figure 8.12 Dr. Reddy’s Laboratories Contract Manufacturing Revenue: Regional Revenue Share (%), FY 2015
Figure 8.13 Forecast Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), 2015-2026
Figure 9.1 Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), 2010-2015
Figure 9.2 Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2010-2015
Figure 9.3 Leading CMOs: Combined Annual Revenue ($bn), 2015-2026
Figure 9.4 Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), 2015-2026
Figure 9.5 Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2015-2020
Figure 9.6 Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2020-2026

★調査レポート[医薬品リーダーシリーズ：医薬品製造受託機関（CMO）上位30社2016-2026] ( Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) 2016-2026 / VGAIN61121) 販売に関する免責事項

[医薬品リーダーシリーズ：医薬品製造受託機関（CMO）上位30社2016-2026] ( Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) 2016-2026 / VGAIN61121) についてEメールでお問い合わせ

◆関連調査資料◆

医薬品リーダーシリーズ：世界の眼薬メーカー上位25社
VGN808068 / visiongain / 2018年7月 / ...The global ophthalmic drugs market was valued at $23bn in 2017. The market was dominated by the Retinal Disorder drug submarket which held 39.1% of the global ophthalmic drugs market. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 223-page report you will receive 83 tables and 71 figures– all unavailable elsewhere. The 223-page report provides clear detailed insight into the top ophthalmic drugs manufacturers. Discover the key drivers and challenges affecting the market. By ordering and reading our brand-new report today you...

ワクチン製造委託の世界市場2016-2026
VGAIN5122112 / visiongain / 2015年12月 / 当調査レポートでは、ワクチン製造委託の世界市場について調査・分析し、以下の構成でお届けいたします。・レポートの概要・ワクチンのヒストリー・ワクチン製造技術動向・世界のワクチン製造市場、市場規模・世界のワクチン製造委託市場、市場規模・主要地域分析・世界のワクチン製造動向・主要企業分析・結論...What can be expected from the vaccine contract manufacturing market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there. Our 148-page report provides 76 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market. Forecasts from 2016-2026 and other analyses show you...

医薬品製造委託の世界市場2016-2026
VGAIN6041532 / visiongain / 2016年3月 / ...Contract drug production – discover trends and markets with highest revenue potentialsWhere is outsourced pharma manufacturing heading? Visiongain’s updated study predicts that industry’s revenues from 2016. There you find potentials for sales growth, also exploring trends, technologies, clients’ needs and opportunities. That new report gives you revenue forecasts to 2026 at overall world market, submarket and national level. Avoid falling behind in data. Instead see what is happening for those medical contracting services – outsourcing and off-shoring – hearing how you can gain and benefit your influence. Please read on to explore that industry and discover what revenue its future...

医療機器リーダーシリーズ：薬剤充填済み注入器トップメーカー2016-2026
VGAIN81927 / visiongain / 2016年8月 / 当調査レポートは以下の構成でお届けいたします。 1. レポート概要 2. 薬剤充填済み注入器の概要 3. プレフィルドシリンジ製造市場における主要企業 4. 薬剤充填済み注入器部品製造市場における主要企業 5....Pre-Filled Syringes and Related Drug Delivery – Discover Leading Companies’ Revenue Potentials How are companies in the pre-filled syringe industry performing? Visiongain’s new report gives you data, analysis and discussions for producers of those drug delivery devices. Our study lets you assess companies in the pre-filled (ready-to-fill) syringe industry and market, showing you their prospects to 2026. There you see financial results, opinion, trends, opportunities and sales predictions. That way you discover potentials of established and rising companies. Read on, please, to scan those organisations and see what their future market could be worth. Forecasts and discussions to help you...

生物学的製剤API（原薬）製造サービスの世界市場予測2016-2026
VGAIN81916 / visiongain / 2016年8月 / 当調査レポートでは、生物学的製剤API（原薬）製造サービスの世界市場について調査・分析し、生物学的製剤API（原薬）製造サービスの世界市場規模、市場動向、市場予測、市場環境分析、専門家の見解、関連企業情報などを含め、以下の構成でお届けいたします。 1. レポート概要 2. バイオテクノロジーAPI製造サービスの概要 3. バイオテクノロジーAPI製造サービス：世界市場見通し・予測 4. バイオテクノロジーAPI製造サービス2次市場：世界市場見通し・予測 5....Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026: Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine reviews the contract active pharmaceutical ingredient (API) manufacturing market for biologics. This study gives quantitative and qualitative analysis for that overall world market, as well as for countries and other submarkets, including the mammalian cell culture and microbial fermentation segments. This report assesses leading applications and significant developments within each, as well as drivers and restraints for them. Future trends that will affect the biotech API manufacturing services market are also examined. In addition, this study...

医療機器委託製造の世界市場予測2016-2026
VGAIN60622 / visiongain / 2016年5月 / 当調査レポートでは、医療機器委託製造の世界市場について調査・分析し、以下の構成でお届けいたします。 1. レポート概要 2. 医療機器委託製造: 概要 3. 医療機器委託製造市場 2016-2026 4....What can be expected from the Medical Device Contract Manufacturing Market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects. Our 234-page report provides 152 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across all the major regional and national medical device contract manufacturing market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market. Forecasts from 2016-2026...

製薬産業向け治験サプライ及び物流の世界市場2016-2026
VGAIN6041530 / visiongain / 2016年3月 / ...Services Supporting Clinical Trials – Discover Your 2016 Guide to That Industry’s Trends, Abilities and Revenue PotentialsWhat does the future hold for companies supplying and assisting clinical trials? Now you can gain data and revenue forecasts for that rising market, helping you stay ahead. Discover that industry’s financial prospects. From 2016 see what is possible. With our study you explore those pharmaceutical R&D needs, trends and opportunities. Visiongain’s updated report gives you revenue forecasts to 2026 at overall world market, submarket and national level. Investigate the high value and potential of those contracting services, seeing how you can benefit. Those...

世界のトップ30医薬品製造受託機関（CMO）
VGAIN5100108 / visiongain / 2015年9月 / ...Contracted drug production – stay ahead now by exploring leading companies’ prospects How are pharma contract manufacturing organisations (CMOs) performing? Visiongain’s updated report shows you their prospects to 2025. You discover that outsourcing industry’s results, trends, opportunities and potentials, also with predicted revenues and profits. Our study analyses 30 top CMOs. There you see how revenues from drug production services can increase. You explore trends, technologies and opportunities shaping that industry. Discover that market’s potential, benefiting your reputation for commercial insight. That way you find analysis on established and emerging companies across the world. Read on, please, to scan the...

医薬品有力企業シリーズ：主要医薬品製造受託機関(CMO)分析
VISION411062 / visiongain / 2014年9月 / 本調査レポートでは、世界の主要医薬品製造受託機関(CMO)について調査・分析し、市場概観、ヨーロッパ市場、主要先進国市場、中国市場、インド市場における医薬品受託製造企業データなどをお届けいたします。・サマリー・イントロダクション：医薬品製造受託市場・主な欧州の医薬品製造受託機関(CMO) ・その他の主要先進市場におけるCMO ・主な先進市場におけるAPIメーカー・主な中国の医薬品製造受託企業・主なインドの医薬品受託製造企業・結論...[Contract manufacturing for pharma – discover top companies’ revenue prospects] How are pharma contract manufacturing organisations (CMOs) performing? Visiongain’s new report shows you their prospects to 2024. There you discover that industry and market’s results, trends, opportunities and prospects, also with predicted revenues and profits. Our study analyses 30 top CMOs. There you see how revenues from drug production services can increase. So what trends, technologies and opportunities most shape the future? You find out, benefiting your knowledge, decisions and authority. That way you discover analysis on established and emerging companies across the world. Read on, then, to scan those...

医薬品契約販売の世界市場2016-2026
VGAIN6041537 / visiongain / 2016年3月 / ...Outsourced Medical Sales – How to Find Pharma Trends, Opportunities and Potential RevenuesAre you interested in the future of outsourced pharmaceutical sales? If so, gain new multilevel forecasts for those promotional activities. With our updated report, stay ahead in data on contract sales organisations (CSOs). See what revenues are possible. Also assess changes sweeping that industry. Avoid getting left behind. Knowledge to help your work – discover how you can benefit your influence So avoid struggles to find data on outsourced drug selling. Our report helps your research, analyses and decisions for medical sales. Save time, too, and help yourself...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆